AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Immunogene vaccination improved the outcome after combination therapy for myeloma murine myeloma.
According to a study from Canada, "Increasing evidence suggests a role for immunologic vaccination and therapy in the management of minimal residual myeloma. We have previously demonstrated a synergistic effect of combining the Th1 stimulating cytokine IL-12 with the co-stimulatory molecule CD80 in murine myeloma vaccination therapy."
"We reasoned that the efficacy of such treatment might be further improved by incorporating additional gene products which enhance the function of antigen presenting cells," said Zhi Hua Li and colleagues at Princess Margaret Hospital in Toronto. "Studies were therefore conducted with murine myeloma BM1 cells expressing Flt3L (membrane bound or soluble forms) or GM-CSF and the IL-12.CD80 combination. Single agent and combined therapeutic approaches were explored."
"All gene-modified BM1 cells, except BM1/IL-12.CD80, developed tumors when subcutaneously injected into BALB/c mice," reported the researchers. "As prophylactic tumor vaccines, the combined use of gene-modified BM1/sFlt3L+GM-CSF+IL-12.CD80 was most effective, providing 100% protection against subsequent parental BM1 tumor ...
Source: HighBeam Research, Immunogene vaccine improves outcome after combination therapy for...